Do you have the same question? Follow this Question
May 13, 2026 - 08:35 AM
We’ve provided several answers to questions related to Voxzogo (Vosoritide) , see some other helpful Q&A related to this product.
Question: Who should not use this medication?
Answer: It is contraindicated in patients with hypersensitivity to vosoritide or any of the excipients, and in patients with closed epiphyses. Contraindications are important to prevent adverse reactions and ensure the medication is only used where it can be effective.
Question: What is the elimination half-life of this medication?
Answer: The elimination half-life is 24 minutes. Half-life refers to how long it takes for half of the medication to be cleared from the body, which is valuable for understanding dosing schedules and the duration of action.
Question: Is Voxzogo approved by the FDA?
Answer: Yes, Voxzogo (vosoritide) is approved by the FDA. It was approved in November 2021 for the treatment of achondroplasia in children aged five years and older with open growth plates.
